Amplification dose group:(1.0-5.0)*10^6 CAR+T cells/kg

2 trials

Sponsors

Shanxi Cancer Hospital, Shanghai Changzheng Hospital Onset

Conditions

Multiple myeloma

Early Phase 1

Clinical study on the safety and effectiveness of targeting CD19 and BCMA CAR - T cells immunotherapy in patients with relapsed or refractory multiple myeloma

RecruitingChiCTR2000041012

Shanxi Cancer HospitalMultiple myeloma

Start: 2020-12-21Updated: 2021-03-01

A safety and efficacy preliminary clinical study of KQ-19B CAR-T cells for the treatment of relapse/refractory multiple myeloma

RecruitingChiCTR2100041955

Shanghai Changzheng Hospital OnsetMultiple myeloma

Start: 2021-01-15Updated: 2021-03-30